Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer

Article

Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.

Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer

Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer

December 8th 2023
Article

Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

breast cancer

Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC

December 8th 2023
Article

The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

breast cancer

Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases

December 7th 2023
Article

The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.

breast cancer

Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials

December 7th 2023
Article

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

© 2023 MJH Life Sciences

All rights reserved.